JAVELIN-GASTRIC-100
Regimen
- Experimental
- avelumab maintenance after 12-week induction chemotherapy
- Control
- continued induction chemotherapy
Population
HER2-negative advanced gastric cancer without progression after 12 weeks of induction chemotherapy
Key finding
mOS 10.4 vs 10.9 mo (HR 0.91, 95% CI 0.74-1.11, p=0.178, NEGATIVE); 24-mo OS 22.1% vs 15.5%; TRAE grade>=3 12.8% vs 32.8%
Source: PMID 33197226
Timeline
Guideline citations
- CSCO GASTRIC 2025 (p.106)⚠️ OCR source